Drugs / GLPG0974
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01721980 | Oct 2012 → Feb 2013 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01829321 | Apr 2013 → Apr 2014 | ulcerative colitis | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLPG0974 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01829321 ↗ |
| Action | Inhibit | “Free fatty acid receptor 2 antagonist” CHEMBL3353541 ↗ |
| Modality | Small molecule | — CHEMBL3353541 ↗ |
| Route | Oral | “50 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days” NCT01721980 ↗ |
| Target | FFAR2 | “Free fatty acid receptor 2 antagonist” CHEMBL3353541 ↗ |